Year |
Citation |
Score |
2021 |
Aquilanti E, Kageler L, Wen PY, Meyerson M. Telomerase as a therapeutic target in glioblastoma. Neuro-Oncology. PMID 34473298 DOI: 10.1093/neuonc/noab203 |
0.316 |
|
2021 |
Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TC, Wong CK, Choi HY, Felau I, Robertson AG, Castro MAA, Bao L, Rheinbay E, Liu EM, Trieu T, ... ... Meyerson M, et al. Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. Cell Reports. 34: 108707. PMID 33535033 DOI: 10.1016/j.celrep.2021.108707 |
0.321 |
|
2021 |
Singh H, Li YY, Spurr LF, Shinagare AB, Abhyankar R, Reilly E, Brais LK, Nag A, Ducar MD, Thorner AR, Shapiro GI, Keller RB, Siletti C, Clark JW, Farago AF, ... ... Meyerson M, et al. Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33414136 DOI: 10.1158/1078-0432.CCR-20-4073 |
0.307 |
|
2020 |
Carrot-Zhang J, Soca-Chafre G, Patterson N, Thorner AR, Nag A, Watson J, Genovese G, Rodriguez J, Gelbard MK, Corrales-Rodriguez L, Mitsuishi Y, Ha G, Campbell JD, Oxnard GR, Arrieta O, ... ... Meyerson M, et al. Genetic ancestry contributes to somatic mutations in lung cancers from admixed Latin American populations. Cancer Discovery. PMID 33268447 DOI: 10.1158/2159-8290.CD-20-1165 |
0.369 |
|
2020 |
Pleguezuelos-Manzano C, Puschhof J, Huber AR, van Hoeck A, Wood HM, Nomburg J, Gurjao C, Manders F, Dalmasso G, Stege PB, Paganelli FL, Geurts MH, Beumer J, Mizutani T, van der Linden R, ... ... Meyerson M, et al. Mutational signature in colorectal cancer caused by genotoxic pks E. coli. Nature. PMID 32106218 DOI: 10.1038/S41586-020-2080-8 |
0.312 |
|
2020 |
Calabrese C, Davidson NR, Demircioğlu D, Fonseca NA, He Y, Kahles A, Lehmann KV, Liu F, Shiraishi Y, Soulette CM, Urban L, Greger L, Li S, Liu D, ... ... Meyerson M, et al. Genomic basis for RNA alterations in cancer. Nature. 578: 129-136. PMID 32025019 DOI: 10.1038/S41586-020-1970-0 |
0.447 |
|
2020 |
Wu X, Schnitzler GR, Gao GF, Diamond B, Baker AR, Kaplan B, Williamson K, Westlake L, Lorrey S, Lewis TA, Garvie CW, Lange M, Hayat S, Seidel H, Doench J, ... ... Meyerson M, et al. Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12. The Journal of Biological Chemistry. PMID 32005668 DOI: 10.1074/Jbc.Ra119.011191 |
0.388 |
|
2020 |
Nomburg J, Bullman S, Collisson E, Mushi B, Seleka M, Vaske C, Newton Y, Radenbuagh A, Akoko L, DeCaprio JA, Meyerson M, Mmbaga EJ, Loon KV. Abstract B06: Investigating the microbial etiology of Tanzanian esophageal squamous cell carcinoma Cancer Research. 80. DOI: 10.1158/1538-7445.Mvc2020-B06 |
0.386 |
|
2020 |
Taylor AM, Jain S, Shih J, Cherniack AD, Beroukhim R, Meyerson M. Abstract A44: Functional models of chromosome arm-level aneuploidies in cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-A44 |
0.326 |
|
2020 |
Zhang X, Meyerson M. Illuminating the noncoding genome in cancer Nature Cancer. 1: 864-872. DOI: 10.1038/S43018-020-00114-3 |
0.376 |
|
2019 |
Llabata P, Mitsuishi Y, Choi PS, Cai D, Francis JM, Torres-Diz M, Udeshi ND, Golomb L, Wu Z, Zhou J, Svinkina T, Aguilera-Jimenez E, Liu Y, Carr SA, Sanchez-Cespedes M, ... Meyerson M, et al. Multi-Omics analysis identifies MGA as a negative regulator of the MYC pathway in lung adenocarcinoma. Molecular Cancer Research : McR. PMID 31862696 DOI: 10.1158/1541-7786.Mcr-19-0657 |
0.381 |
|
2019 |
Lewis TA, de Waal L, Wu X, Youngsaye W, Wengner A, Kopitz C, Lange M, Gradl S, Ellermann M, Lienau P, Schreiber SL, Greulich H, Meyerson M. Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing. Acs Medicinal Chemistry Letters. 10: 1537-1542. PMID 31749907 DOI: 10.1021/Acsmedchemlett.9B00360 |
0.302 |
|
2019 |
Kim M, Mun H, Sung CO, Cho EJ, Jeon HJ, Chun SM, Jung DJ, Shin TH, Jeong GS, Kim DK, Choi EK, Jeong SY, Taylor AM, Jain S, Meyerson M, et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nature Communications. 10: 3991. PMID 31488816 DOI: 10.1038/S41467-019-11867-6 |
0.381 |
|
2019 |
Zou T, Meyerson M. Circulating Tumor DNA Provides a Sneak Peek into Treatment Responses in Non-Small Cell Lung Cancer. Cancer Research. 79: 1038-1040. PMID 30877100 DOI: 10.1158/0008-5472.Can-19-0231 |
0.361 |
|
2019 |
Jin C, Lagoudas GK, Zhao C, Bullman S, Bhutkar A, Hu B, Ameh S, Sandel D, Liang XS, Mazzilli S, Whary MT, Meyerson M, Germain R, Blainey PC, Fox JG, et al. Commensal Microbiota Promote Lung Cancer Development via γδ T Cells. Cell. PMID 30712876 DOI: 10.1016/J.Cell.2018.12.040 |
0.329 |
|
2019 |
Cai D, Choi PS, Gelbard M, Meyerson M. Identification and characterization of oncogenic SOS1 mutations in lung adenocarcinoma. Molecular Cancer Research : McR. PMID 30635434 DOI: 10.1158/1541-7786.Mcr-18-0316 |
0.368 |
|
2019 |
Stover EH, Baco MB, Cohen O, Li Y, Christie E, Bagul M, Goodale A, Lee Y, Pantel S, Rees M, Wei G, Presser A, Zervantonakis I, Bhola P, Ryan J, ... ... Meyerson M, et al. Abstract AP14: POOLED GENOMIC SCREENS IDENTIFY ANTI-APOPTOTIC GENES AS MEDIATORS OF CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Ap14 |
0.302 |
|
2019 |
Goldstein JT, Berger AC, Strathdee CA, Meyerson M. Abstract 1026: Oncogenic alterations in FGFR3 and ERBB2 lead to ligand-independent activation of PPARG in bladder cancer Cancer Research. 79: 1026-1026. DOI: 10.1158/1538-7445.Am2019-1026 |
0.457 |
|
2019 |
Zou T, Meyerson M. IBS05.02 Functional Genomic Approaches to Identify Novel Therapeutic Targets in Lung Cancer Journal of Thoracic Oncology. 14: S93. DOI: 10.1016/j.jtho.2019.08.209 |
0.375 |
|
2018 |
Gannon HS, Zou T, Kiessling MK, Gao GF, Cai D, Choi PS, Ivan AP, Buchumenski I, Berger AC, Goldstein JT, Cherniack AD, Vazquez F, Tsherniak A, Levanon EY, Hahn WC, ... Meyerson M, et al. Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nature Communications. 9: 5450. PMID 30575730 DOI: 10.1038/S41467-018-07824-4 |
0.439 |
|
2018 |
Kosumi K, Hamada T, Koh H, Borowsky J, Bullman S, Twombly TS, Nevo D, Masugi Y, Liu L, da Silva A, Chen Y, Du C, Gu M, Li C, Li W, ... ... Meyerson ML, et al. The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. The American Journal of Pathology. PMID 30243655 DOI: 10.1016/J.Ajpath.2018.08.015 |
0.304 |
|
2018 |
Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, Howard TP, Takeda DY, Ly SH, Kim E, Gannon HS, Hurhula B, Sharpe T, Goodale A, Fritchman B, ... ... Meyerson M, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nature Genetics. PMID 30224644 DOI: 10.1038/S41588-018-0204-Y |
0.338 |
|
2018 |
Ben-David U, Siranosian B, Ha G, Tang H, Oren Y, Hinohara K, Strathdee CA, Dempster J, Lyons NJ, Burns R, Nag A, Kugener G, Cimini B, Tsvetkov P, Maruvka YE, ... ... Meyerson M, et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. PMID 30089904 DOI: 10.1038/S41586-018-0409-3 |
0.334 |
|
2018 |
Yurgelun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Qian ZR, Welch MW, Brais LK, Da Silva A, Bui JL, Yuan C, Li T, Li W, Masuda A, ... ... Meyerson ML, et al. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 29961768 DOI: 10.1038/S41436-018-0009-5 |
0.388 |
|
2018 |
Viswanathan SR, Nogueira MF, Buss CG, Krill-Burger JM, Wawer MJ, Malolepsza E, Berger AC, Choi PS, Shih J, Taylor AM, Tanenbaum B, Pedamallu CS, Cherniack AD, Tamayo P, Strathdee CA, ... ... Meyerson M, et al. Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nature Genetics. PMID 29955178 DOI: 10.1038/S41588-018-0155-3 |
0.395 |
|
2018 |
Viswanathan SR, Ha G, Hoff AM, Wala JA, Carrot-Zhang J, Whelan CW, Haradhvala NJ, Freeman SS, Reed SC, Rhoades J, Polak P, Cipicchio M, Wankowicz SA, Wong A, Kamath T, ... ... Meyerson M, et al. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell. PMID 29909985 DOI: 10.1016/J.Cell.2018.05.036 |
0.329 |
|
2018 |
Bockorny B, Rusan M, Chen W, Liao RG, Li Y, Piccioni F, Wang J, Tan L, Thorner AR, Li T, Zhang Y, Miao CH, Ovesen T, Shapiro GI, Kwiatkowski DJ, ... ... Meyerson M, et al. RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade. Molecular Cancer Therapeutics. PMID 29654068 DOI: 10.1158/1535-7163.Mct-17-0464 |
0.324 |
|
2018 |
Bullman S, Zou T, Meyerson M. Mechanistic Insights into Transmissible Cancers of Mammals. Cancer Cell. 33: 543-544. PMID 29634941 DOI: 10.1016/J.Ccell.2018.03.019 |
0.335 |
|
2018 |
Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, ... ... Meyerson M, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 173: 321-337.e10. PMID 29625050 DOI: 10.1016/J.Cell.2018.03.035 |
0.38 |
|
2018 |
Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ, Cherniack AD, Beroukhim R, Meyerson M. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell. PMID 29622463 DOI: 10.1016/J.Ccell.2018.03.007 |
0.429 |
|
2018 |
Cho J, Kim S, Du J, Meyerson M. Autophosphorylation of the C-terminal domain is not required for oncogenic transformation by lung-cancer derived EGFR mutants. International Journal of Cancer. PMID 29464683 DOI: 10.1002/Ijc.31332 |
0.31 |
|
2018 |
Lewis TA, Waal Ld, Wu X, Ellerman M, Kopitz C, Wengner A, Eis K, Lange M, Tersteegen A, Lienau P, Greulich H, Meyerson M. Abstract 5880: Small-molecule modulators of PDE3/SLFN12 to kill cancer cells Cancer Research. 78: 5880-5880. DOI: 10.1158/1538-7445.Am2018-5880 |
0.361 |
|
2018 |
Bullman S, Pedamallu CS, Sicinska E, Clancy T, Ogino S, Tabernero J, Fuchs C, Hahn WC, Nuciforo P, Meyerson M. Abstract 5129: Fusobacterium and co-occurring microbes in primary and metastatic colorectal cancer Cancer Research. 78: 5129-5129. DOI: 10.1158/1538-7445.Am2018-5129 |
0.411 |
|
2018 |
Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La K, Dimitriadoy S, Liu DL, Kantheti HS, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, ... ... Meyerson M, et al. Abstract 3302: The molecular landscape of oncogenic signaling pathways in The Cancer Genome Atlas Cancer Research. 78: 3302-3302. DOI: 10.1158/1538-7445.Am2018-3302 |
0.435 |
|
2018 |
Taylor AM, Zhang X, Shih J, Ha G, Gao GF, Berger AC, Cherniack AD, Beroukhim R, Meyerson M. Abstract 3002: Genome engineering approaches to generate models of chromosome arm-level cancer aneuploidy Cancer Research. 78: 3002-3002. DOI: 10.1158/1538-7445.Am2018-3002 |
0.302 |
|
2018 |
Ben-David U, Siranosian B, Ha G, Tang H, Lyons NJ, Burns R, Nag A, Cimini B, Tsvetkov P, Tubelli AA, Wong B, Thorner AR, Bittker J, Meyerson M, Beroukhim R, et al. Abstract 214: Genetic and transcriptional instability alters cell line drug response Cancer Research. 78: 214-214. DOI: 10.1158/1538-7445.Am2018-214 |
0.38 |
|
2017 |
Berger AH, Brooks AN, Wu X, Shrestha Y, Chouinard C, Piccioni F, Bagul M, Kamburov A, Imielinski M, Hogstrom L, Zhu C, Yang X, Pantel S, Sakai R, Watson J, ... ... Meyerson M, et al. High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell. 32: 884. PMID 29232558 DOI: 10.1016/j.ccell.2017.11.008 |
0.382 |
|
2017 |
Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, Neuberg D, Huang K, Guevara F, Nelson T, Chipashvili O, Hagan T, Walker M, Ramachandran A, Diosdado B, ... ... Meyerson M, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science (New York, N.Y.). PMID 29170280 DOI: 10.1126/Science.Aal5240 |
0.419 |
|
2017 |
Zhang X, Choi PS, Francis JM, Gao GF, Campbell JD, Ramachandran A, Mitsuishi Y, Ha G, Shih J, Vazquez F, Tsherniak A, Taylor AM, Zhou J, Wu Z, Berger AC, ... ... Meyerson M, et al. Somatic super-enhancer duplications and hotspot mutations lead to oncogenic activation of the KLF5 transcription factor. Cancer Discovery. PMID 28963353 DOI: 10.1158/2159-8290.Cd-17-0532 |
0.49 |
|
2017 |
Goldstein JT, Berger AC, Shih J, Duke FF, Furst L, Kwiatkowski DJ, Cherniack AD, Meyerson M, Strathdee CA. Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer. Cancer Research. PMID 28923856 DOI: 10.1158/0008-5472.Can-17-1701 |
0.474 |
|
2017 |
Rheinbay E, Parasuraman P, Grimsby J, Tiao G, Engreitz JM, Kim J, Lawrence MS, Taylor-Weiner A, Rodriguez-Cuevas S, Rosenberg M, Hess J, Stewart C, Maruvka YE, Stojanov P, Cortes ML, ... ... Meyerson M, et al. Recurrent and functional regulatory mutations in breast cancer. Nature. PMID 28658208 DOI: 10.1038/Nature22992 |
0.379 |
|
2017 |
Lu X, Peled N, Greer J, Wu W, Choi P, Berger AH, Wong S, Jen KY, Seo Y, Hann B, Brooks A, Meyerson M, Collisson EA. MET exon 14 mutation encodes an actionable therapeutic target in lung adenocarcinoma. Cancer Research. PMID 28522754 DOI: 10.1158/0008-5472.Can-16-1944 |
0.352 |
|
2017 |
Campbell JD, Lathan C, Sholl L, Ducar M, Vega M, Sunkavalli A, Lin L, Hanna M, Schubert L, Thorner A, Faris N, Williams DR, Osarogiagbon RU, van Hummelen P, Meyerson M, et al. Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations. Jama Oncology. 3: 801-809. PMID 28114446 DOI: 10.1001/Jamaoncol.2016.6108 |
0.349 |
|
2017 |
Imielinski M, Guo G, Meyerson M. Insertions and Deletions Target Lineage-Defining Genes in Human Cancers. Cell. PMID 28089356 DOI: 10.1016/J.Cell.2016.12.025 |
0.436 |
|
2017 |
Stover DG, Parsons HA, Ha G, Freeman S, Barry WT, Guo H, Gydush G, Reed S, Rhoades J, Rotem D, Hughes ME, Krop IE, Tolaney SM, Wagle N, Getz G, ... Meyerson M, et al. Genome-wide copy number analysis of cell-free DNA from patients with chemotherapy-resistant metastatic triple-negative breast cancer. Journal of Clinical Oncology. 35: 1092-1092. DOI: 10.1200/Jco.2017.35.15_Suppl.1092 |
0.318 |
|
2017 |
Meyers RM, Aguirre AJ, Weir BA, Vazquez F, Zhang C, Ben-David U, Cook A, Ha G, Harrington WF, Doshi M, Gill S, Xu H, Ali LD, Jiang G, Pantel S, ... ... Meyerson M, et al. Abstract B39: Genomic copy number alterations introduce a gene-independent viability bias in CRISPR-Cas9 knock-out screens of cancer cell lines Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-B39 |
0.434 |
|
2017 |
Li J, Choi P, Chaffer C, Labella K, Kim JW, Doench J, Dai C, Giacomelli A, Ly SH, Hwang J, Hong A, Ilic N, Gjoerup O, Meyerson M, Brooks A, et al. Abstract A36: Genome-scale ORF screening to identify modulators of the epithelial-to-mesenchymal transition Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-A36 |
0.315 |
|
2017 |
Nishihara R, Chan AT, Mu JX, Giannakis M, Mima K, Qian ZR, Bullman S, Kostic AD, Huttenhower C, Garrett W, Giovannucci EL, Meyerson M, Garraway LA, Fuchs CS, Ogino S. Abstract PR01:Fusobacterium nucleatumand mutational landscape of colorectal cancer in whole-exome sequencing analysis Cancer Research. 77. DOI: 10.1158/1538-7445.Crc16-Pr01 |
0.357 |
|
2017 |
Amin S, Awadalla P, Biankin A, Boutros P, Brazma A, Brooks AN, Calabrese C, Chang D, Chateigner A, Chen K, Chong Z, Craft B, Creighton C, Demircioğlu D, Fonseca N, ... ... Meyerson M, et al. Abstract SY10-02: Pan-cancer study of recurrent and heterogeneous RNA aberrations and association with whole-genome variants Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Sy10-02 |
0.313 |
|
2017 |
Li J, Choi P, Chaffer C, Labella K, Kim JW, Doench J, Dai C, Giacomelli A, Ly SH, Hwang J, Hong A, Ilic N, Gjoerup O, Meyerson M, Brooks A, et al. Abstract 5020: A genome-scale ORF screen reveals an alternative splicing program that regulates mesenchymal and stem-like cell states in breast cancer Cancer Research. 77: 5020-5020. DOI: 10.1158/1538-7445.Am2017-5020 |
0.314 |
|
2017 |
Gannon HS, Kiessling M, Vazquez F, Hahn W, Meyerson M. Abstract 4616: Exploring the role of interferon and innate immune regulators in outlier cancer cell line survival Cancer Research. 77: 4616-4616. DOI: 10.1158/1538-7445.Am2017-4616 |
0.406 |
|
2017 |
Goldstein JT, Strathdee C, Duke F, Shih J, Meyerson M. Abstract 3627: Validation of PPARG and RXRA as drivers of bladder cancer Cancer Research. 77: 3627-3627. DOI: 10.1158/1538-7445.Am2017-3627 |
0.459 |
|
2017 |
Nishihara R, Chan AT, Mu J, Giannakis M, Mima K, Qian ZR, Bullman S, Kostic A, Huttenhower C, Garrett W, Giovannucci E, Meyerson M, Garraway L, Fuchus C, Ogino S. Whole-exome sequencing analyses of colorectal cancer with Fusobacterium nucleatum The Faseb Journal. 31. DOI: 10.1096/Fasebj.31.1_Supplement.178.12 |
0.308 |
|
2017 |
Taylor A, Gavin H, Shih J, Zhang X, Campbell J, Andrew C, Meyerson M. Genome Engineering to Generate Models of Chromosome Arm-Level Aneuploidies in Lung Cancer Journal of Thoracic Oncology. 12: S1545. DOI: 10.1016/J.Jtho.2017.06.057 |
0.31 |
|
2017 |
Meyerson M. Somatic Genome Changes in Human Non–Small Cell Lung Cancers Journal of Thoracic Oncology. 12: S1539. DOI: 10.1016/J.JTHO.2017.06.034 |
0.387 |
|
2016 |
Shankar GM, Abedalthagafi M, Vaubel RA, Merrill PH, Nayyar N, Gill CM, Brewster R, Bi WL, Agarwalla PK, Thorner AR, Reardon DA, Al-Mefty O, Wen PY, Alexander BM, van Hummelen P, ... ... Meyerson M, et al. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-Oncology. PMID 28170043 DOI: 10.1093/Neuonc/Now235 |
0.302 |
|
2016 |
Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, ... ... Meyerson M, et al. Institutional implementation of clinical tumor profiling on an unselected cancer population. Jci Insight. 1: e87062. PMID 27882345 DOI: 10.1172/Jci.Insight.87062 |
0.419 |
|
2016 |
Berger AH, Brooks AN, Wu X, Shrestha Y, Chouinard C, Piccioni F, Bagul M, Kamburov A, Imielinski M, Hogstrom L, Zhu C, Yang X, Pantel S, Sakai R, Watson J, ... ... Meyerson M, et al. High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell. PMID 27478040 DOI: 10.1016/J.Ccell.2016.06.022 |
0.373 |
|
2016 |
Aguirre AJ, Meyers RM, Weir BA, Vazquez F, Zhang CZ, Ben-David U, Cook A, Ha G, Harrington WF, Doshi MB, Kost-Alimova M, Gill S, Xu H, Ali LD, Jiang G, ... Meyerson M, et al. Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting. Cancer Discovery. PMID 27260156 DOI: 10.1158/2159-8290.Cd-16-0154 |
0.348 |
|
2016 |
Holst F, Hoivik EA, Gibson WJ, Taylor-Weiner A, Schumacher SE, Asmann YW, Grossmann P, Trovik J, Necela BM, Thompson EA, Meyerson M, Beroukhim R, Salvesen HB, Cherniack AD. Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Scientific Reports. 6: 25521. PMID 27160768 DOI: 10.1038/Srep25521 |
0.333 |
|
2016 |
Aguirre AJ, Shao W, Xu H, Weir B, Vazquez F, Meyers R, Zhang C, Doshi M, Cowley GS, Ewachiw T, Rasheed Z, Golub TR, Stegmaier K, Roberts CW, Garraway LA, ... Meyerson M, et al. Abstract PR05: Genome-scale CRISPR-Cas9 screening to identify essential genes and pathways in pancreatic cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-Pr05 |
0.339 |
|
2016 |
Adalsteinsson VA, Ha G, Freeman S, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed S, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Cohen O, Oh C, Kim J, ... ... Meyerson M, et al. Abstract LB-136: High concordance of whole-exome sequencing of cell-free DNA and matched biopsies enables genomic discovery in metastatic cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-136 |
0.4 |
|
2016 |
Campbell JD, Perdomo C, Mazzilli S, Geshalter Y, Dhillon SS, Liu G, Zhang S, Lin H, Vick J, Moy C, Johnson E, Meyerson M, Platero S, Lenburg M, Reid M, et al. Abstract 895: Genomic characterization of premalignant lung squamous cell carcinoma lesions Cancer Research. 76: 895-895. DOI: 10.1158/1538-7445.Am2016-895 |
0.359 |
|
2016 |
Berger AH, Brooks AN, Wu X, Shrestha Y, Chouinard C, Piccioni F, Bagul M, Kamburov A, Imielinski M, Hogstrom L, Zhu C, Yang X, Pantel S, Sakai R, Kaplan N, ... ... Meyerson M, et al. Abstract 4368: High-throughput phenotyping of lung cancer somatic mutations Cancer Research. 76: 4368-4368. DOI: 10.1158/1538-7445.Am2016-4368 |
0.428 |
|
2016 |
Pedamallu CS, Meyerson M, Ojesina A. Abstract 3301: Breast cancer subtypes have distinct microbial and immune cytolytic transcriptomic signatures Cancer Research. 76: 3301-3301. DOI: 10.1158/1538-7445.Am2016-3301 |
0.344 |
|
2015 |
Zhang X, Choi PS, Francis JM, Imielinski M, Watanabe H, Cherniack AD, Meyerson M. Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nature Genetics. PMID 26656844 DOI: 10.1038/Ng.3470 |
0.502 |
|
2015 |
de Waal L, Lewis TA, Rees MG, Tsherniak A, Wu X, Choi PS, Gechijian L, Hartigan C, Faloon PW, Hickey MJ, Tolliday N, Carr SA, Clemons PA, Munoz B, Wagner BK, ... ... Meyerson M, et al. Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. Nature Chemical Biology. PMID 26656089 DOI: 10.1038/Nchembio.1984 |
0.399 |
|
2015 |
Gannon HS, Kaplan N, Tsherniak A, Vazquez F, Weir BA, Hahn WC, Meyerson M. Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-targeted Therapy. Molecular Cancer Research : McR. PMID 26582713 DOI: 10.1158/1541-7786.Mcr-15-0321 |
0.411 |
|
2015 |
Terai H, Tan L, Beauchamp EM, Hatcher JM, Liu Q, Meyerson M, Gray NS, Hammerman PS. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer. Acs Chemical Biology. PMID 26390252 DOI: 10.1021/Acschembio.5B00655 |
0.37 |
|
2015 |
Xu C, Buczkowski KA, Zhang Y, Asahina H, Beauchamp EM, Terai H, Li YY, Meyerson M, Wong KK, Hammerman PS. NSCLC Driven by DDR2 Mutation is Sensitive to Dasatinib and JQ1 Combination Therapy. Molecular Cancer Therapeutics. PMID 26206333 DOI: 10.1158/1535-7163.Mct-15-0077 |
0.427 |
|
2015 |
van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J, Taylor-Weiner A, Kester L, McLaren-Douglas A, Blokker J, Jaksani S, Bartfeld S, Volckman R, ... ... Meyerson M, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 161: 933-45. PMID 25957691 DOI: 10.1016/J.Cell.2015.03.053 |
0.346 |
|
2015 |
Ramos AH, Lichtenstein L, Gupta M, Lawrence MS, Pugh TJ, Saksena G, Meyerson M, Getz G. Oncotator: cancer variant annotation tool. Human Mutation. 36: E2423-9. PMID 25703262 DOI: 10.1002/Humu.22771 |
0.428 |
|
2015 |
Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, Seepo S, Meyerson M, Pass HI. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Research. 75: 264-9. PMID 25488749 DOI: 10.1158/0008-5472.Can-14-1008 |
0.301 |
|
2015 |
Bellmunt J, Guo G, Mullane SA, Orsola A, Werner L, Van Hummelen P, Thorner A, Loda M, Choueiri TK, Barletta JA, Kwiatkowski DJ, Meyerson M, Van Allen EM. Genomic landscape of high-grade T1 micropapillary bladder tumors. Journal of Clinical Oncology. 33: 299-299. DOI: 10.1200/Jco.2015.33.7_Suppl.299 |
0.304 |
|
2015 |
Murray B, Albiges L, Van Allen EM, Cherniack A, Fay AP, Meyerson M, Choueiri TK. Precision medicine approach in kidney cancer: A pan renal cell carcinoma (RCC) study across three cancer genome atlas (TCGA) datasets for clinically relevant target identification. Journal of Clinical Oncology. 33: 4564-4564. DOI: 10.1200/Jco.2015.33.15_Suppl.4564 |
0.394 |
|
2015 |
Albiges L, Murray B, Brooks A, Cherniack A, Berger A, Creighton CJ, Ricketts C, Bottaro DP, Srinivasan R, Schmidt LS, Meyerson M, Spellman P, Linehan WM, Choueiri TK. Distinct MET alterations to induce a common phenotype and to define a MET-driven subset of papillary RCC: Results from the Cancer Genome Atlas (TCGA) Kidney Renal Papillary (KIRP) Working Group. Journal of Clinical Oncology. 33: 4521-4521. DOI: 10.1200/Jco.2015.33.15_Suppl.4521 |
0.318 |
|
2015 |
Berger A, Brooks A, Wu X, Hogstrom L, Tirosh I, Piccioni F, Bagul M, Zhu C, Shretha Y, Root D, Tamayo P, Sakai R, Wong B, Subramanian A, Golub T, ... Meyerson M, et al. Abstract PR12: High-throughput gene expression profiling as a generalizable assay for determination of mutation impact on gene function Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-Pr12 |
0.382 |
|
2015 |
Berger AH, Kim E, Brooks A, Ilic N, Shrestha Y, Tseng Y, Wu X, Zou L, Kamburov A, Yang X, Zhu C, Keskula P, Seepo S, Hong A, Kantoff P, ... ... Meyerson M, et al. Abstract PR07: Towards precision functional genomics via next-generation functional mapping of cancer variants Cancer Research. 75: 957-957. DOI: 10.1158/1538-7445.Transcagen-Pr07 |
0.481 |
|
2015 |
Berger A, Brooks A, Wu X, Hogstrom L, Tirosh I, Piccioni F, Bagul M, Zhu C, Shretha Y, Root D, Tamayo P, Sakai R, Wong B, Subramanian A, Golub T, ... Meyerson M, et al. Abstract PR04: High-throughput gene expression profiling as a generalizable assay for determination of mutation impact on gene function Cancer Research. 75. DOI: 10.1158/1538-7445.Compsysbio-Pr04 |
0.378 |
|
2015 |
Brooks AN, Ge Y, Chau K, Freeman SS, Saksena G, Pedamallu CS, Meyerson M. Abstract B2-21: Identification of somatic RNA splicing alterations in human cancers Cancer Research. 75. DOI: 10.1158/1538-7445.Compsysbio-B2-21 |
0.455 |
|
2015 |
Campbell J, Lathan C, Sholl L, Ducar M, Vega M, Lin L, Thorner A, Faris N, Hummelen Pv, Osarogiagbon R, Meyerson M, MacConaill L. Abstract 3886: Comparing the mutational landscape of African American and Caucasian lung cancers Cancer Research. 75: 3886-3886. DOI: 10.1158/1538-7445.Am2015-3886 |
0.35 |
|
2015 |
Abazeed M, Yard B, Adams D, Tamayo P, Hearn J, Chie EK, Schreiber S, Meyerson M, Peacock C, Hammerman P. Abstract 3315: Functional genomic profiling of lung adenocarcinoma identifies BRAF mutations as novel therapeutic targets Cancer Research. 75: 3315-3315. DOI: 10.1158/1538-7445.Am2015-3315 |
0.469 |
|
2015 |
Waal Ld, Lewis TA, Rees MG, Tsherniak A, Wu X, Choi PS, Gechijian L, Hartigan C, Faloon PW, Hickey MJ, Tolliday N, Carr SA, Clemons PA, Munoz B, Wagner BK, ... ... Meyerson M, et al. Abstract C136: Identification of selective cancer cytotoxic modulators of phosphodiesterase 3a by predictive chemogenomics Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C136 |
0.396 |
|
2015 |
Abazeed M, Adams D, Hammerman P, Tamayo P, Yard B, Meyerson M, Schreiber S. Systematic Investigation of Genetic Vulnerabilities Across Cancer Cell Lines Reveals Lineage Specific Radiotherapeutic Determinants International Journal of Radiation Oncology*Biology*Physics. 93: S143-S144. DOI: 10.1016/J.Ijrobp.2015.07.340 |
0.338 |
|
2014 |
Sharifnia T, Rusu V, Piccioni F, Bagul M, Imielinski M, Cherniack AD, Pedamallu CS, Wong B, Wilson FH, Garraway LA, Altshuler D, Golub TR, Root DE, Subramanian A, Meyerson M. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: 18661-6. PMID 25512530 DOI: 10.1073/Pnas.1412228112 |
0.323 |
|
2014 |
Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, ... ... Meyerson M, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 26: 319-30. PMID 25155756 DOI: 10.1016/J.Ccr.2014.07.014 |
0.39 |
|
2014 |
Tchaicha JH, Akbay EA, Altabef A, Mikse OR, Kikuchi E, Rhee K, Liao RG, Bronson RT, Sholl LM, Meyerson M, Hammerman PS, Wong KK. Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC. Cancer Research. 74: 4676-84. PMID 25035393 DOI: 10.1158/0008-5472.Can-13-3218 |
0.399 |
|
2014 |
Cho J, Bass AJ, Lawrence MS, Cibulskis K, Cho A, Lee SN, Yamauchi M, Wagle N, Pochanard P, Kim N, Park AK, Won J, Hur HS, Greulich H, Ogino S, ... ... Meyerson M, et al. Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Molecular Cancer. 13: 141. PMID 24894453 DOI: 10.1186/1476-4598-13-141 |
0.368 |
|
2014 |
Helman E, Lawrence MS, Stewart C, Sougnez C, Getz G, Meyerson M. Somatic retrotransposition in human cancer revealed by whole-genome and exome sequencing. Genome Research. 24: 1053-63. PMID 24823667 DOI: 10.1101/gr.163659.113 |
0.455 |
|
2014 |
Choi PS, Meyerson M. Targeted genomic rearrangements using CRISPR/Cas technology. Nature Communications. 5: 3728. PMID 24759083 DOI: 10.1038/Ncomms4728 |
0.317 |
|
2014 |
Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis JM, Zhang CZ, Shalek AK, Satija R, Trombetta JJ, Lu D, Tallapragada N, Tahirova N, Kim S, ... ... Meyerson M, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nature Biotechnology. 32: 479-84. PMID 24752078 DOI: 10.1038/Nbt.2892 |
0.373 |
|
2014 |
Watanabe H, Brooks AN, Meyerson M. Breaking down RET breakpoints in lung adenocarcinoma. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 590-2. PMID 24722148 DOI: 10.1097/Jto.0000000000000168 |
0.3 |
|
2014 |
Imielinski M, Greulich H, Kaplan B, Araujo L, Amann J, Horn L, Schiller J, Villalona-Calero MA, Meyerson M, Carbone DP. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. The Journal of Clinical Investigation. 124: 1582-6. PMID 24569458 DOI: 10.1172/Jci72763 |
0.394 |
|
2014 |
Brooks AN, Choi PS, de Waal L, Sharifnia T, Imielinski M, Saksena G, Pedamallu CS, Sivachenko A, Rosenberg M, Chmielecki J, Lawrence MS, DeLuca DS, Getz G, Meyerson M. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. Plos One. 9: e87361. PMID 24498085 DOI: 10.1371/Journal.Pone.0087361 |
0.432 |
|
2014 |
Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak RGW, McConkey D, Lerner S, Morgan M, Creighton CJ, Smith C, Cherniack AD, Kim J, Pedamallu CS, Noble MS, Al-Ahmadie HA, ... ... Meyerson M, et al. Comprehensive molecular characterization of urothelial bladder carcinoma Nature. 507: 315-322. PMID 24476821 DOI: 10.1038/Nature12965 |
0.413 |
|
2014 |
Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, ... ... Meyerson M, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discovery. 4: 216-31. PMID 24436047 DOI: 10.1158/2159-8290.Cd-13-0639 |
0.337 |
|
2014 |
Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 505: 495-501. PMID 24390350 DOI: 10.1038/Nature12912 |
0.731 |
|
2014 |
Kim Y, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, Wilkerson MD, Pedamallu CS, Cibulskis K, Yoo YK, Lawrence MS, Stojanov P, Carter SL, McKenna A, Stewart C, ... ... Meyerson M, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 121-8. PMID 24323028 DOI: 10.1200/Jco.2013.50.8556 |
0.394 |
|
2014 |
Beauchamp EM, Woods BA, Dulak AM, Tan L, Xu C, Gray NS, Bass AJ, Wong KK, Meyerson M, Hammerman PS. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Molecular Cancer Therapeutics. 13: 475-82. PMID 24296828 DOI: 10.1158/1535-7163.Mct-13-0817 |
0.376 |
|
2014 |
Chmielecki J, Meyerson M. DNA sequencing of cancer: what have we learned? Annual Review of Medicine. 65: 63-79. PMID 24274178 DOI: 10.1146/Annurev-Med-060712-200152 |
0.31 |
|
2014 |
Rosenberg JE, Kim J, Cherniack A, Sougnez C, Meyerson M, Getz G, Weinstein JN, Lerner SP, Kwiatkowski DJ. Somatic genomic alterations in urothelial cancer: Results of the Cancer Genome Atlas (TCGA) bladder cancer (BC) analysis. Journal of Clinical Oncology. 32: 285-285. DOI: 10.1200/Jco.2014.32.4_Suppl.285 |
0.464 |
|
2014 |
Berger AH, Brooks AN, Imielinski M, Cherniack A, Duke F, Kaplan N, Wala J, Meyerson M. Abstract PR08:NF1,MET, andRIT1mutations are RAS-pathway driver events in lung adenocarcinoma Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-Pr08 |
0.371 |
|
2014 |
Adalsteinsson VA, Lohr JG, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis J, Zhang C, Shalek AK, Satija R, Trombetta JT, Lu D, Tallapragada N, Tahirova NT, Kim S, ... ... Meyerson M, et al. Abstract 993: Whole exome sequencing of CTCs as a window into metastatic cancer Cancer Research. 74: 993-993. DOI: 10.1158/1538-7445.Am2014-993 |
0.407 |
|
2014 |
Kim H, Zheng S, Amini SS, Virk SM, Mikkelsen T, Brat DJ, Grimsby J, Sougnez C, Sloan AE, Cohen ML, Meir EGV, Scarpace L, Laird PW, Weinstein JN, Lander E, ... ... Meyerson M, et al. Abstract 984: Alteration of the p53 pathway is associated with subclonal tumor progression in glioblastoma Cancer Research. 74: 984-984. DOI: 10.1158/1538-7445.Am2014-984 |
0.313 |
|
2014 |
Abo RP, Garcia EP, Ducar M, Adusumilli R, Breneiser M, Rojas-Rudilla V, Sholl LM, Lindeman NI, Meyerson ML, Hahn WC, Hummelen PV, MacConaill LE. Abstract 5321: BreaKmer: Detection of structural rearrangements in targeted next-generation sequencing data using kmers Cancer Research. 74: 5321-5321. DOI: 10.1158/1538-7445.Am2014-5321 |
0.318 |
|
2014 |
Ojesina AI, Murray B, Bjorge L, Woie K, Krakstad C, Lichtenstein L, Pedamallu CS, Taylor-Weiner A, Freeman SS, Cherniack AD, Lawrence MS, Cibulskis K, Carter SL, Walline H, Carey TE, ... ... Meyerson M, et al. Abstract 4692: Relationships between somatic genomic alterations, tumor stage and progression-free survival in cervical cancer Cancer Research. 74: 4692-4692. DOI: 10.1158/1538-7445.Am2014-4692 |
0.353 |
|
2014 |
Abazeed M, Adams D, Tamayo P, Meyerson M, Hammerman P, Schreiber S. Abstract 4259: The radiogenomic landscape of cancer Cancer Research. 74: 4259-4259. DOI: 10.1158/1538-7445.Am2014-4259 |
0.412 |
|
2014 |
Kim Y, Hammerman PS, Kim J, Getz G, Meyerson M, Park K. Abstract 1526: Integrative and comparative genomic analysis of East-Asian lung squamous cell carcinomas Cancer Research. 74: 1526-1526. DOI: 10.1158/1538-7445.Am2014-1526 |
0.412 |
|
2014 |
Berger AH, Duke F, Imielinski M, Kaplan N, Wala J, Shi G, Andres DA, Meyerson M. Abstract PR02: Recurrent oncogenic mutations in the small GTPaseRIT1activate PI3K and MEK. Clinical Cancer Research. 20: PR02-PR02. DOI: 10.1158/1078-0432.14Aacriaslc-Pr02 |
0.364 |
|
2014 |
Abazeed M, Xu C, Adams D, Tamayo P, Loeffler J, Suh J, Meyerson M, Wong K, Hammerman P. NRF2 Is a Novel Oncogene and Biomarker of Therapeutic Resistance in Non-Small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 90: S53. DOI: 10.1016/J.Ijrobp.2014.08.252 |
0.378 |
|
2014 |
Abazeed M, Adams D, Tamayo P, Yard B, Loeffler J, Suh J, Meyerson M, Hammerman P, Schreiber S. The Radiogenomic Landscape of Cancer International Journal of Radiation Oncology*Biology*Physics. 90: S34. DOI: 10.1016/J.Ijrobp.2014.05.145 |
0.393 |
|
2014 |
Imielinski M, Hammerman PS, Thomas R, Meyerson M. Somatic Genome Alterations in Human Lung Cancers Lung Cancer: Fourth Edition. 67-89. DOI: 10.1002/9781118468791.ch4 |
0.382 |
|
2013 |
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, ... ... Meyerson M, et al. The somatic genomic landscape of glioblastoma. Cell. 155: 462-77. PMID 24120142 DOI: 10.1016/J.Cell.2013.09.034 |
0.372 |
|
2013 |
Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, Lawrence MS, Zhsng CZ, Wala J, Mermel CH, Sougnez C, Gabriel SB, Hernandez B, Shen H, Laird PW, ... ... Meyerson M, et al. Pan-cancer patterns of somatic copy number alteration. Nature Genetics. 45: 1134-40. PMID 24071852 DOI: 10.1038/Ng.2760 |
0.748 |
|
2013 |
Hanna MC, Go C, Roden C, Jones RT, Pochanard P, Javed AY, Javed A, Mondal C, Palescandolo E, Van Hummelen P, Hatton C, Bass AJ, Chun SM, Na DC, Kim TI, ... ... Meyerson M, et al. Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. Plos One. 8: e74950. PMID 24066160 DOI: 10.1371/Journal.Pone.0074950 |
0.375 |
|
2013 |
Abazeed ME, Adams DJ, Hurov KE, Tamayo P, Creighton CJ, Sonkin D, Giacomelli AO, Du C, Fries DF, Wong KK, Mesirov JP, Loeffler JS, Schreiber SL, Hammerman PS, Meyerson M. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Research. 73: 6289-98. PMID 23980093 DOI: 10.1158/0008-5472.Can-13-1616 |
0.342 |
|
2013 |
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, ... ... Meyerson M, et al. Signatures of mutational processes in human cancer. Nature. 500: 415-21. PMID 23945592 DOI: 10.1038/Nature12477 |
0.424 |
|
2013 |
Liao RG, Jung J, Tchaicha J, Wilkerson MD, Sivachenko A, Beauchamp EM, Liu Q, Pugh TJ, Pedamallu CS, Hayes DN, Gray NS, Getz G, Wong KK, Haddad RI, Meyerson M, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Research. 73: 5195-205. PMID 23786770 DOI: 10.1158/0008-5472.Can-12-3950 |
0.332 |
|
2013 |
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, ... ... Meyerson M, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 499: 214-8. PMID 23770567 DOI: 10.1038/Nature12213 |
0.715 |
|
2013 |
Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, Theurillat JP, Soong TD, ... ... Meyerson M, et al. Punctuated evolution of prostate cancer genomes. Cell. 153: 666-77. PMID 23622249 DOI: 10.1016/J.Cell.2013.03.021 |
0.356 |
|
2013 |
Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature Biotechnology. 31: 213-9. PMID 23396013 DOI: 10.1038/Nbt.2514 |
0.341 |
|
2013 |
Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, ... ... Meyerson M, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. The Journal of Clinical Investigation. 123: 517-25. PMID 23257362 DOI: 10.1172/Jci65833 |
0.661 |
|
2013 |
Drier Y, Lawrence MS, Carter SL, Stewart C, Gabriel SB, Lander ES, Meyerson M, Beroukhim R, Getz G. Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Research. 23: 228-35. PMID 23124520 DOI: 10.1101/Gr.141382.112 |
0.346 |
|
2013 |
Meyerson M. Abstract IA2: Somatic alterations in human cancer genomes Cancer Research. 73. DOI: 10.1158/1538-7445.Fbcr13-Ia2 |
0.439 |
|
2013 |
Solimini N, Pavlova NN, Mermel C, Xu Q, Burrows AE, Luo J, li M, Beroukhim R, Meyerson M, Elledge SJ. Abstract SY25-03: Haploinsufficiency in cancer: When half simply isn't good enough. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Sy25-03 |
0.643 |
|
2013 |
Liao RG, Sivachenko A, Getz G, Dutt A, Hammerman PS, Meyerson M. Abstract 963: Characterizing acquired resistance mechanisms to targeted therapy in FGFR1-amplified lung squamous cell carcinoma. Cancer Research. 73: 963-963. DOI: 10.1158/1538-7445.Am2013-963 |
0.341 |
|
2013 |
Hummelen PV, Ducar M, Jones RT, Raza A, Sunkavalli A, Hanna M, Mills A, Adusumilli R, Kumar P, Schubert L, Breneiser M, Cooley AC, Garcia E, Scholl LM, Lindeman NI, ... ... Meyerson ML, et al. Abstract 819: Targeted sequencing to detect somatic mutations, translocations and copy-number variation in human tumors simultaneously. Cancer Research. 73: 819-819. DOI: 10.1158/1538-7445.Am2013-819 |
0.431 |
|
2013 |
Ojesina AI, Lichtenstein L, Ambrogio L, Cibulskis K, Freeman S, Pedamallu CS, Bertelsen B, Imaz I, Vazquez K, Guadarrama AS, Treviño V, Romero-Cordoba S, Duke F, Kaplan B, Rodriguez I, ... ... Meyerson ML, et al. Abstract 4604: Landscape of human and viral genomic alterations in cervical carcinomas. Cancer Research. 73: 4604-4604. DOI: 10.1158/1538-7445.Am2013-4604 |
0.34 |
|
2013 |
Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Allen EV, Kryukov GV, Theurillat J, Soong TD, Nickerson E, Auclair D, ... ... Meyerson M, et al. Abstract 4601: Punctuated evolution of prostate cancer genomes. Cancer Research. 73: 4601-4601. DOI: 10.1158/1538-7445.Am2013-4601 |
0.38 |
|
2013 |
Carter SL, Landau D, Stojanov P, McKenna A, Cibulskis K, Lawrence MS, Lohr J, Stevenson K, Neuberg D, Meyerson M, Wu CJ, Getz G. Abstract 4600: Analysis of clonal evolution in cancer using whole exome sequence data reveals that subclonal driver mutations predict poor prognosis in chronic lymphocytic leukemia. Cancer Research. 73: 4600-4600. DOI: 10.1158/1538-7445.Am2013-4600 |
0.404 |
|
2013 |
Bhatt AS, Pedamallu CS, Duke F, Jung J, Freeman SS, Cherniak A, Park R, Kim J, Kwiatkowski D, Rosenberg J, Meyerson M. Abstract 4149: Transcriptomic and pathogen analysis in bladder cancer primary tumor and metastasis pairs. Cancer Research. 73: 4149-4149. DOI: 10.1158/1538-7445.Am2013-4149 |
0.446 |
|
2013 |
Sasaki MM, Skol AD, Pugh TJ, Meyerson M, Onel K. Abstract 4018: Whole exome sequencing analysis of familial Medulloblastoma. Cancer Research. 73: 4018-4018. DOI: 10.1158/1538-7445.Am2013-4018 |
0.397 |
|
2013 |
Prandi D, Baca SC, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Allen EV, Kryukov GV, Theurillat J, Soong TD, Nickerson E, Auclair D, ... ... Meyerson M, et al. Abstract 4017: Dissecting the clonal hierarchy of cancer-driving genomic lesions. Cancer Research. 73: 4017-4017. DOI: 10.1158/1538-7445.Am2013-4017 |
0.381 |
|
2013 |
Pugh TJ, Yu W, Yang J, Ambrogio L, Carter SL, Kiezun A, McKenna A, Giannikopoulos P, Getz G, Messinger Y, Meyerson M, Hill DA. Abstract 3806: Progressive biallelic loss of TP53 is associated with progression of pleuropulmonary blastoma initiated by germline loss and somatic mutation of DICER1. Cancer Research. 73: 3806-3806. DOI: 10.1158/1538-7445.Am2013-3806 |
0.316 |
|
2013 |
Watanabe H, Francis JM, Woo MS, Etemad B, Lin W, Fries DF, Peng S, Snyder EL, Tata PR, Schinzel AC, Cho J, Hammerman PS, Verhaak RG, Hahn WC, Rajagopal J, ... ... Meyerson M, et al. Abstract 3127: Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Cancer Research. 73: 3127-3127. DOI: 10.1158/1538-7445.Am2013-3127 |
0.346 |
|
2013 |
Jung J, Pedamallu CS, Kostic AD, Freeman S, Ojesina AI, Berger A, Bhatt A, Duke F, Getz G, Meyerson M. Abstract 1501: Pan-cancer PathSeq analysis on TCGA data for pathogen discovery. Cancer Research. 73: 1501-1501. DOI: 10.1158/1538-7445.Am2013-1501 |
0.397 |
|
2013 |
Chmielecki J, Rosenberg M, Imielinski M, Hernandez B, Lawrence M, Sivachenko A, Cibulskis K, Voet D, Sougnez C, Gabriel S, Getz G, Meyerson M. Abstract 1112: Whole exome and whole genome sequence analysis of lung adenocarcinoma. Cancer Research. 73: 1112-1112. DOI: 10.1158/1538-7445.Am2013-1112 |
0.457 |
|
2013 |
Berger A, Imielinski M, Duke F, Wala J, Kaplan N, Shi G, Andres D, Meyerson M. Abstract C140: RIT1 mutations define a new genetic subset of lung adenocarcinoma. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C140 |
0.354 |
|
2013 |
Greulich HE, Imielinski M, Kaplan B, Araujo L, Amann J, Horn L, Villalona M, Meyerson M, Carbone D. Abstract C139: Oncogenic ARAF mutation in a metastatic lung adenocarcinoma from a patient exhibiting sustained sorafenib response. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C139 |
0.42 |
|
2013 |
Kim H, Zheng S, Amini SS, Virk S, Mikkelsen T, Brat DJ, Grimsby J, Sougnez C, Sloan AE, Cohen ML, Meir EGV, Scarpace L, Laird PW, Weinstein JN, Lander ES, ... ... Meyerson M, et al. Abstract B130: The intratumoral heterogeneity of glioblastoma suggests a pivotal role for clonal evolution. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B130 |
0.401 |
|
2013 |
Abazeed M, Adams D, Hurov K, Tamayo P, Creighton C, Sonkin D, Giacomelli A, Schreiber S, Hammerman P, Meyerson M. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 87: S138-S139. DOI: 10.1016/J.IJROBP.2013.06.356 |
0.377 |
|
2012 |
Liao RG, Watanabe H, Meyerson M, Hammerman PS. Targeted therapy for squamous cell lung cancer. Lung Cancer Management. 1: 293-300. PMID 23956794 DOI: 10.2217/Lmt.12.40 |
0.317 |
|
2012 |
Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, ... ... Meyerson M, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 150: 1107-20. PMID 22980975 DOI: 10.1016/J.Cell.2012.08.029 |
0.373 |
|
2012 |
Hammerman PS, Voet D, Lawrence MS, Jing R, Cibulskis K, Sivachenko A, Stojanov P, McKenna A, Lander ES, Gabriel S, Getz G, Imielinski M, Helman E, Hernandez B, Pho NH, ... Meyerson M, et al. Comprehensive genomic characterization of squamous cell lung cancers Nature. 489: 519-525. PMID 22960745 DOI: 10.1038/Nature11404 |
0.477 |
|
2012 |
Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, ... ... Meyerson M, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics. 44: 1104-10. PMID 22941188 DOI: 10.1038/Ng.2396 |
0.426 |
|
2012 |
Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, Cho YJ, Pugh TJ, Hovestadt V, Stütz AM, Rausch T, Warnatz HJ, Ryzhova M, Bender S, Sturm D, ... ... Meyerson M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature. 488: 100-5. PMID 22832583 DOI: 10.1038/Nature11284 |
0.315 |
|
2012 |
Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4973-85. PMID 22806877 DOI: 10.1158/1078-0432.Ccr-11-2967 |
0.319 |
|
2012 |
Dulak AM, Schumacher SE, van Lieshout J, Imamura Y, Fox C, Shim B, Ramos AH, Saksena G, Baca SC, Baselga J, Tabernero J, Barretina J, Enzinger PC, Corso G, Roviello F, ... ... Meyerson M, et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Research. 72: 4383-93. PMID 22751462 DOI: 10.1158/0008-5472.Can-11-3893 |
0.423 |
|
2012 |
Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, ... ... Meyerson M, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 486: 405-9. PMID 22722202 DOI: 10.1038/Nature11154 |
0.387 |
|
2012 |
Solimini NL, Xu Q, Mermel CH, Liang AC, Schlabach MR, Luo J, Burrows AE, Anselmo AN, Bredemeyer AL, Li MZ, Beroukhim R, Meyerson M, Elledge SJ. Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science (New York, N.Y.). 337: 104-9. PMID 22628553 DOI: 10.1126/Science.1219580 |
0.69 |
|
2012 |
Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, ... ... Meyerson M, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 485: 502-6. PMID 22622578 DOI: 10.1038/Nature11071 |
0.304 |
|
2012 |
Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, ... ... Meyerson M, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genetics. 44: 685-9. PMID 22610119 DOI: 10.1038/Ng.2279 |
0.36 |
|
2012 |
Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, Ducar M, Van Hummelen P, Macconaill LE, Hahn WC, Meyerson M, Gabriel SB, Garraway LA. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discovery. 2: 82-93. PMID 22585170 DOI: 10.1158/2159-8290.CD-11-0184 |
0.321 |
|
2012 |
Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, Laird PW, Onofrio RC, Winckler W, Weir BA, Beroukhim R, Pellman D, Levine DA, Lander ES, Meyerson M, et al. Absolute quantification of somatic DNA alterations in human cancer. Nature Biotechnology. 30: 413-21. PMID 22544022 DOI: 10.1038/Nbt.2203 |
0.428 |
|
2012 |
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, ... ... Meyerson M, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483: 603-7. PMID 22460905 DOI: 10.1038/Nature11003 |
0.406 |
|
2012 |
Lin L, Bass AJ, Lockwood WW, Wang Z, Silvers AL, Thomas DG, Chang AC, Lin J, Orringer MB, Li W, Glover TW, Giordano TJ, Lam WL, Meyerson M, Beer DG. Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America. 109: 4251-6. PMID 22375031 DOI: 10.1073/Pnas.1011989109 |
0.365 |
|
2012 |
Basseres DS, D'Alò F, Yeap BY, Löwenberg EC, Gonzalez DA, Yasuda H, Dayaram T, Kocher ON, Godleski JJ, Richards WG, Meyerson M, Kobayashi S, Tenen DG, Halmos B, Costa DB. Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. Lung Cancer (Amsterdam, Netherlands). 77: 31-7. PMID 22341411 DOI: 10.1016/J.Lungcan.2012.01.011 |
0.371 |
|
2012 |
Jänne PA, Meyerson M. ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 878-9. PMID 22215755 DOI: 10.1200/Jco.2011.39.4197 |
0.38 |
|
2012 |
Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, Baselga J, Liu C, Shivdasani RA, Ogino S, Birren BW, ... ... Meyerson M, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Research. 22: 292-8. PMID 22009990 DOI: 10.1101/Gr.126573.111 |
0.303 |
|
2012 |
Govindan R, Hammerman PS, Hayes DN, Wilkerson MD, Baylin S, Meyerson M. Comprehensive genomic characterization of squamous cell carcinoma of the lung. Journal of Clinical Oncology. 30: 7006-7006. DOI: 10.1200/Jco.2012.30.15_Suppl.7006 |
0.328 |
|
2012 |
Locasale JW, Grassian A, Beroukhim R, Meyerson M, Wagner G, Asara JM, Brugge JS, Vander Heiden MG, Cantley LC. Amplification of phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis Bmc Proceedings. 6. DOI: 10.1186/1753-6561-6-S3-O15 |
0.372 |
|
2012 |
Solimini NL, Bredemeyer AL, Li MZ, Beroukhim R, Meyerson M, Elledge SJ, Pavlova NN, Xu Q, Mermel CH, Liang AC, Schlabach MR, Luo J, Burrows AE, Anselmo AN. Abstract IA8: Genetic approaches to cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Csb12-Ia8 |
0.706 |
|
2012 |
Helman E, Lawrence M, Stewart C, Getz G, Meyerson M. Abstract 5060: Identification of somatic retrotransposon insertions across cancer types using RetroSeq Cancer Research. 72: 5060-5060. DOI: 10.1158/1538-7445.Am2012-5060 |
0.44 |
|
2012 |
Hodis E, Watson I, Theurillat J, Zou L, Place C, Nickerson E, Auclair D, Cibulskis K, Sivachenko A, Kryukov G, Stransky N, Ramos AH, Voet D, Lawrence MS, Stojanov P, ... ... Meyerson M, et al. Abstract 5056: A glimpse into the somatic mutation landscape of melanoma through exome sequencing of 121 tumor-normal pairs Cancer Research. 72: 5056-5056. DOI: 10.1158/1538-7445.Am2012-5056 |
0.376 |
|
2012 |
Jones DT, Jaeger N, Cho Y, Pugh TJ, Rausch T, Stuetz A, Zichner T, Weischenfeldt J, Zapatka M, Benes V, Blake J, Northcott PA, Remke M, Witt H, Witt O, ... ... Meyerson ML, et al. Abstract 4872: ICGC PedBrain Tumor - Next-generation sequencing identifies novel subgroup-specific mutations and copy number aberrations in medulloblastoma Cancer Research. 72: 4872-4872. DOI: 10.1158/1538-7445.Am2012-4872 |
0.415 |
|
2012 |
Pugh TJ, Cho Y, Archer T, Weeraratne D, Jones DTW, Jaeger N, Auclair D, Cibulskis K, Lawrence MS, Ramos AH, Shefler E, Sivachenko A, Tamayo P, Mesirov JP, Gabriel SB, ... ... Meyerson M, et al. Abstract 4868: Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations within a wide spectrum of genetic heterogeneity Cancer Research. 72: 4868-4868. DOI: 10.1158/1538-7445.Am2012-4868 |
0.319 |
|
2012 |
Basseres DS, D'Alò F, Yeap BY, Gonzalez DA, Yasuda H, Meyerson M, Kobayashi S, Tenen DG, Halmos B, Costa DB. Abstract 4036: Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing Cancer Research. 72: 4036-4036. DOI: 10.1158/1538-7445.Am2012-4036 |
0.421 |
|
2012 |
Liao R, Hammerman P, Sivachenko A, Greulich H, Getz G, Liu Q, Gray N, Meyerson M. Abstract 2: FGFR3 as a therapeutic target in squamous cell lung carcinoma Cancer Research. 72: 2-2. DOI: 10.1158/1538-7445.Am2012-2 |
0.426 |
|
2012 |
Imielinski M, Hernandez B, Lawrence M, Hodis E, Kryukov G, Stojanov P, Sivachenko A, Cibulskis K, Sougnez C, Auclair D, Ardlie K, Banerji S, Hammerman P, Thomas RK, Gabriel S, ... ... Meyerson M, et al. Abstract 1682: Uncovering signals of somatic selection through whole exome and whole genome sequencing of lung adenocarcinoma Cancer Research. 72: 1682-1682. DOI: 10.1158/1538-7445.Am2012-1682 |
0.411 |
|
2012 |
Greulich H, Kaplan B, Mertins P, Chen T, Tanaka K, Yun C, Imielinski M, Banerji S, Lawrence MS, Walker S, Winckler W, Getz G, Frank D, Eck M, Jaffe JD, ... ... Meyerson M, et al. Abstract 1: Oncogenic extracellular domain mutations of ERBB2 in cancer Cancer Research. 72: 1-1. DOI: 10.1158/1538-7445.Am2012-1 |
0.302 |
|
2012 |
Hernandez B, Hammerman P, Imielinski M, Lawrence M, Stojanov P, Getz G, Meyerson M. Abstract PR1: Integrating expression data improves mutational significance analysis of lung squamous carcinoma Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.12Aacriaslc-Pr1 |
0.46 |
|
2012 |
Meyerson M. Abstract IA7: Somatic genome alterations in human lung cancers Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.12Aacriaslc-Ia7 |
0.411 |
|
2012 |
Liao RG, Hammerman P, Sivachencko A, Greulich H, Getz G, Liu Q, Gray N, Meyerson M. Abstract B13: FGFR2 as a therapeutic target in squamous cell lung carcinoma Clinical Cancer Research. 18: B13-B13. DOI: 10.1158/1078-0432.12Aacriaslc-B13 |
0.391 |
|
2012 |
Banerji S, Cibulskis K, Rangel-Escareño C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, ... ... Meyerson M, et al. Abstract PL07-01: Molecular profiling of breast cancer in Mexico: Identification of novel therapeutic targets through whole genome sequencing analysis. Cancer Epidemiology, Biomarkers & Prevention. 21. DOI: 10.1158/1055-9965.Disp12-Pl07-01 |
0.358 |
|
2012 |
Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, Fulton LL, Dooling DJ, Ding L, Mardis ER, Wilson RK, Ally A, Balasundaram M, Butterfield YSN, Carlsen R, ... ... Meyerson M, et al. Comprehensive molecular portraits of human breast tumours Nature. 490: 61-70. DOI: 10.1038/Nature11412 |
0.358 |
|
2011 |
Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X, Butaney M, Sequist LV, Luo B, Engelman JA, Root DE, Meyerson M, Golub TR, Jänne PA, Hahn WC. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discovery. 1: 608-25. PMID 22586683 DOI: 10.1158/2159-8290.Cd-11-0046 |
0.35 |
|
2011 |
Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, ... ... Meyerson M, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery. 1: 78-89. PMID 22328973 DOI: 10.1158/2159-8274.Cd-11-0005 |
0.465 |
|
2011 |
Fudenberg G, Getz G, Meyerson M, Mirny LA. High order chromatin architecture shapes the landscape of chromosomal alterations in cancer. Nature Biotechnology. 29: 1109-13. PMID 22101486 DOI: 10.1038/Nbt.2049 |
0.366 |
|
2011 |
MacConaill LE, Van Hummelen P, Meyerson M, Hahn WC. Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discovery. 1: 297-311. PMID 21935500 DOI: 10.1158/2159-8290.Cd-11-0110 |
0.387 |
|
2011 |
Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, Sougnez C, Voet D, Saksena G, Sivachenko A, Jing R, Parkin M, Pugh T, Verhaak RG, Stransky N, ... ... Meyerson M, et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nature Genetics. 43: 964-8. PMID 21892161 DOI: 10.1038/Ng.936 |
0.407 |
|
2011 |
Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, Sasaki AT, Anastasiou D, Mullarky E, Vokes NI, Sasaki M, ... ... Meyerson M, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nature Genetics. 43: 869-74. PMID 21804546 DOI: 10.1038/Ng.890 |
0.364 |
|
2011 |
Dooley AL, Winslow MM, Chiang DY, Banerji S, Stransky N, Dayton TL, Snyder EL, Senna S, Whittaker CA, Bronson RT, Crowley D, Barretina J, Garraway L, Meyerson M, Jacks T. Nuclear factor I/B is an oncogene in small cell lung cancer. Genes & Development. 25: 1470-5. PMID 21764851 DOI: 10.1101/Gad.2046711 |
0.414 |
|
2011 |
Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, East A, Ali LD, Lizotte PH, Wong TC, Jiang G, Hsiao J, Mermel CH, Getz G, Barretina J, ... ... Meyerson M, et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 108: 12372-7. PMID 21746896 DOI: 10.1073/Pnas.1109363108 |
0.75 |
|
2011 |
Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, Gray NS, Meyerson M. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. Plos One. 6: e20351. PMID 21666749 DOI: 10.1371/Journal.Pone.0020351 |
0.669 |
|
2011 |
Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biology. 12: R41. PMID 21527027 DOI: 10.1186/Gb-2011-12-4-R41 |
0.676 |
|
2011 |
Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage MJ, Whittaker CA, Hoersch S, Yoon S, Crowley D, Bronson RT, Chiang DY, Meyerson M, et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature. 473: 101-4. PMID 21471965 DOI: 10.1038/Nature09881 |
0.34 |
|
2011 |
Wilbertz T, Wagner P, Petersen K, Stiedl AC, Scheble VJ, Maier S, Reischl M, Mikut R, Altorki NK, Moch H, Fend F, Staebler A, Bass AJ, Meyerson M, Rubin MA, et al. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 24: 944-53. PMID 21460799 DOI: 10.1038/Modpathol.2011.49 |
0.318 |
|
2011 |
Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, ... ... Meyerson M, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 471: 467-72. PMID 21430775 DOI: 10.1038/Nature09837 |
0.376 |
|
2011 |
Chin L, Hahn WC, Getz G, Meyerson M. Making sense of cancer genomic data. Genes & Development. 25: 534-55. PMID 21406553 DOI: 10.1101/Gad.2017311 |
0.381 |
|
2011 |
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, ... ... Meyerson M, et al. The genomic complexity of primary human prostate cancer. Nature. 470: 214-20. PMID 21307934 DOI: 10.1038/Nature09744 |
0.322 |
|
2011 |
Barretina J, Stransky N, Caponigro G, Kim S, Margolin A, Venkhatesan K, Kryukov G, Berger M, Monahan J, Morais P, Meltzer J, Mahan S, Sonkin D, Raman P, Jones M, ... ... Meyerson M, et al. Abstract 5455: Integrative analysis of the Cancer Cell Line Encyclopedia reveals genetic and transcriptional predictors of compound sensitivity Cancer Research. 71: 5455-5455. DOI: 10.1158/1538-7445.Am2011-5455 |
0.441 |
|
2011 |
Banerji S, Barretina J, Crago A, Frederick A, Okamoto M, Weir B, Cowley G, Root D, Ladanyi M, Singer S, Meyerson ML. Abstract 4972: High-throughput functional profiling of dedifferentiated liposarcoma cell lines Cancer Research. 71: 4972-4972. DOI: 10.1158/1538-7445.Am2011-4972 |
0.382 |
|
2011 |
Pugh TJ, Lawrence M, Sougnez C, Getz G, Attiyeh E, Hogarty M, Diskin S, Yael M, Diamond M, Asgharzadeh S, Sposto R, Wei JS, Badgett T, London WB, Gastier-Foster J, ... ... Meyerson ML, et al. Abstract 4756: Exome sequencing of 81 neuroblastomas identifies a wide diversity of somatic mutation Cancer Research. 71: 4756-4756. DOI: 10.1158/1538-7445.Am2011-4756 |
0.358 |
|
2011 |
Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA. Abstract 3933: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling Cancer Research. 71: 3933-3933. DOI: 10.1158/1538-7445.Am2011-3933 |
0.315 |
|
2011 |
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, ... ... Meyerson M, et al. Abstract 3925: Characterization of complex chromosomal aberrations in prostate cancer from whole genome sequencing Cancer Research. 71: 3925-3925. DOI: 10.1158/1538-7445.Am2011-3925 |
0.388 |
|
2011 |
Fudenberg G, Getz G, Meyerson M, Mirny L. High-order chromatin architecture determines the landscape of chromosomal alterations in cancer Nature Precedings. 6: 1-1. DOI: 10.1038/Npre.2011.6356.1 |
0.382 |
|
2010 |
Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing Nature Reviews Genetics. 11: 685-696. PMID 20847746 DOI: 10.1038/Nrg2841 |
0.38 |
|
2010 |
Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, Pintilie M, Der S, Seymour L, Jurisica I, Shepherd FA, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4417-24. PMID 20823422 DOI: 10.1200/Jco.2009.26.4325 |
0.372 |
|
2010 |
Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin Y, ... ... Meyerson M, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics. 42: 715-21. PMID 20601955 DOI: 10.1038/Ng.619 |
0.673 |
|
2010 |
Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T, Stiedl AC, Petersen K, Reischl M, Kuefer R, Schilling D, Fend F, Kristiansen G, Meyerson M, Rubin MA, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 23: 1061-7. PMID 20473283 DOI: 10.1038/Modpathol.2010.87 |
0.67 |
|
2010 |
Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, Moustafa Z, Thomas RK, Greulich H, Schinzel A, Zaghlul S, Batt D, Ettenberg S, Meyerson M, Schoeberl B, et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 17: 298-310. PMID 20227043 DOI: 10.1016/J.Ccr.2009.12.047 |
0.436 |
|
2010 |
Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, Johnson LA, Robinson J, Verhaak RG, Sougnez C, Onofrio RC, Ziaugra L, Cibulskis K, Laine E, Barretina J, ... ... Meyerson M, et al. Integrative analysis of the melanoma transcriptome. Genome Research. 20: 413-27. PMID 20179022 DOI: 10.1101/Gr.103697.109 |
0.392 |
|
2010 |
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, ... ... Meyerson M, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 463: 899-905. PMID 20164920 DOI: 10.1038/Nature08822 |
0.738 |
|
2010 |
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, ... ... Meyerson M, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17: 98-110. PMID 20129251 DOI: 10.1016/J.Ccr.2009.12.020 |
0.359 |
|
2010 |
Liang MC, Ma J, Chen L, Kozlowski P, Qin W, Li D, Goto J, Shimamura T, Hayes DN, Meyerson M, Kwiatkowski DJ, Wong KK. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene. 29: 1588-97. PMID 19966866 DOI: 10.1038/Onc.2009.452 |
0.393 |
|
2010 |
MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, ... ... Meyerson ML, et al. Correction: Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples Plos One. 5. DOI: 10.1371/Annotation/3A0C8Fee-57Ef-43Ed-B6C2-55B503E6Db5E |
0.306 |
|
2010 |
Dooley AL, Winslow MM, Chiang D, Banerji S, Whittaker C, Bronson R, Crowley D, Meyerson M, Jacks T. Abstract LB-146: Identification of copy number alterations in small cell lung cancer Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-146 |
0.437 |
|
2010 |
Wagle N, Davis M, Berger MF, Blumenstiel B, Defelice M, Hahn W, Meyerson M, Gabriel SB, MacConaill L, Garraway LA. Abstract LB-122: High-throughput tumor genomic profiling by massively parallel sequencing Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-122 |
0.38 |
|
2010 |
Beroukhim R, Meyerson M, Garraway L, Prensner J. Abstract 5759: The landscape of copy-number changes across multiple human cancer types Cancer Research. 70: 5759-5759. DOI: 10.1158/1538-7445.Am10-5759 |
0.472 |
|
2010 |
Barretina J, Caponigro G, Kim S, Stransky N, Venkhatesan K, Reddy V, Berger M, Morrissey M, Morais P, Meltzer J, Thibault J, Mahan S, Sonkin D, Che J, Raman P, ... ... Meyerson M, et al. Abstract 2620: The Cancer Cell Line Encyclopedia project: From integrative cancer genomics to personalized cancer therapy Cancer Research. 70: 2620-2620. DOI: 10.1158/1538-7445.Am10-2620 |
0.493 |
|
2010 |
Berger MF, Lawrence MS, Cibulskis K, Pflueger D, Demichelis F, Sougnez C, Onofrio RC, Ambrogio L, Fennell T, Parkin M, Carter SL, Saksena G, Sivachenko A, Voet D, Wilkinson J, ... ... Meyerson M, et al. Abstract 1139: Complete characterization of prostate cancer genomes by massively parallel sequencing Cancer Research. 70: 1139-1139. DOI: 10.1158/1538-7445.Am10-1139 |
0.383 |
|
2010 |
Stransky N, Venkhatesan K, Morrissey M, Barretina J, Raman P, Getz G, Berger M, Johannessen C, Callahan A, Morais P, Mahan S, Gupta S, Onofrio R, Sougnez C, Winckler W, ... ... Meyerson M, et al. Abstract 105: Integrative analysis of genomic and pharmacologic data from the Cancer Cell Line Encyclopedia Cancer Research. 70: 105-105. DOI: 10.1158/1538-7445.Am10-105 |
0.446 |
|
2010 |
Stransky N, Venkatesan K, Barretina J, Caponigro G, Margolin A, Morrissey M, Raman P, Getz G, Berger M, Johannessen C, Callahan A, Morais P, Mahan S, Gupta S, Onofrio R, ... ... Meyerson M, et al. Abstract PR4: Integrative analysis of genomic and pharmacologic data from the Cancer Cell Line Encyclopedia Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-Pr4 |
0.405 |
|
2009 |
MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, ... ... Meyerson ML, et al. Profiling critical cancer gene mutations in clinical tumor samples. Plos One. 4: e7887. PMID 19924296 DOI: 10.1371/Journal.Pone.0007887 |
0.347 |
|
2009 |
Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Fröhling S, Chan EM, Sos ML, Michel K, Mermel C, ... ... Meyerson M, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 462: 108-12. PMID 19847166 DOI: 10.1038/Nature08460 |
0.713 |
|
2009 |
Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, Ramos AH, Woo MS, Weir BA, Getz G, Beroukhim R, ... ... Meyerson M, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genetics. 41: 1238-42. PMID 19801978 DOI: 10.1038/Ng.465 |
0.681 |
|
2009 |
Wagner PL, Perner S, Rickman DS, LaFargue CJ, Kitabayashi N, Johnstone SF, Weir BA, Meyerson M, Altorki NK, Rubin MA. In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma. American Journal of Clinical Pathology. 132: 500-5. PMID 19762526 DOI: 10.1309/Ajcpf10Zunsolifg |
0.35 |
|
2009 |
Ramos AH, Dutt A, Mermel C, Perner S, Cho J, Lafargue CJ, Johnson LA, Stiedl AC, Tanaka KE, Bass AJ, Barretina J, Weir BA, Beroukhim R, Thomas RK, Minna JD, ... ... Meyerson M, et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biology & Therapy. 8: 2042-50. PMID 19755855 DOI: 10.4161/Cbt.8.21.9764 |
0.681 |
|
2009 |
Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O'Sullivan M, Lu J, Phillips LA, Lockhart VL, Shah SP, Tanwar PS, Mermel CH, Beroukhim R, Azam M, ... ... Meyerson M, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nature Genetics. 41: 843-8. PMID 19483683 DOI: 10.1038/Ng.392 |
0.624 |
|
2009 |
Sos ML, Michel K, Zander T, Weiss J, Frommolt P, Peifer M, Li D, Ullrich R, Koker M, Fischer F, Shimamura T, Rauh D, Mermel C, Fischer S, Stückrath I, ... ... Meyerson M, et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. The Journal of Clinical Investigation. 119: 1727-40. PMID 19451690 DOI: 10.1172/Jci37127 |
0.711 |
|
2009 |
Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, ... ... Meyerson M, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Research. 69: 3256-61. PMID 19351834 DOI: 10.1158/0008-5472.Can-08-4055 |
0.66 |
|
2009 |
Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bø TH, Jonassen I, Thomas RK, ... ... Meyerson M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America. 106: 4834-9. PMID 19261849 DOI: 10.1073/Pnas.0806514106 |
0.375 |
|
2009 |
Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, Lade S, Akslen LA, Tinker AV, Locandro B, Alsop K, ... ... Meyerson M, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1417-27. PMID 19193619 DOI: 10.1158/1078-0432.Ccr-08-1564 |
0.702 |
|
2009 |
Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ, Pflueger D, Pina C, Hofer MD, Sboner A, Svensson MA, Rickman DS, Urban A, Snyder M, Meyerson M, et al. Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes, Chromosomes & Cancer. 48: 366-80. PMID 19156837 DOI: 10.1002/Gcc.20647 |
0.339 |
|
2009 |
Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL, Zaghlul S, Brandstetter KA, Kubo S, Takahashi M, Chirieac LR, Padera RF, Bronson RT, Shapiro GI, ... ... Meyerson M, et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proceedings of the National Academy of Sciences of the United States of America. 106: 474-9. PMID 19122144 DOI: 10.1073/Pnas.0808930106 |
0.339 |
|
2009 |
Chiang DY, Getz G, Jaffe DB, O'Kelly MJ, Zhao X, Carter SL, Russ C, Nusbaum C, Meyerson M, Lander ES. High-resolution mapping of copy-number alterations with massively parallel sequencing. Nature Methods. 6: 99-103. PMID 19043412 DOI: 10.1038/Nmeth.1276 |
0.337 |
|
2009 |
MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, ... ... Meyerson ML, et al. Correction: Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples Plos One. 4. DOI: 10.1371/annotation/613c7509-e4c9-42ac-82fb-fc504400d9e0 |
0.382 |
|
2009 |
Greulich H, Chheda M, Chen T, Tanaka K, Dutt A, Wong K, Hahn W, Meyerson M. Abstract A199: Oncogenic and drug‐sensitive ERBB2 mutations in glioblastoma Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A199 |
0.372 |
|
2009 |
Boehm JS, Cowley G, Weir B, Barretina J, Luo B, Cheung HW, Rusin S, Scott J, Derr A, Tsherniak A, Gopalakrishnan S, Tamayo P, Barbie D, Yang X, Piqani B, ... ... Meyerson M, et al. Abstract A23: An integrated platform for the functional annotation of the cancer genome Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-A23 |
0.484 |
|
2009 |
Greulich H, Chheda M, Chen T, Tanaka K, Dutt A, Wong K, Hahn W, Meyerson M. Abstract A2: Oncogenic and drug‐sensitiveERBB2mutations in glioblastoma Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-A2 |
0.384 |
|
2008 |
Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang X, Hinkle G, Boehm JS, Beroukhim R, Weir BA, Mermel C, Barbie DA, Awad T, Zhou X, Nguyen T, ... ... Meyerson M, et al. Highly parallel identification of essential genes in cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 105: 20380-5. PMID 19091943 DOI: 10.1073/Pnas.0810485105 |
0.754 |
|
2008 |
Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, ... ... Meyerson M, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 455: 1069-75. PMID 18948947 DOI: 10.1038/Nature07423 |
0.415 |
|
2008 |
George RE, Sanda T, Hanna M, Fröhling S, Luther W, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, ... ... Meyerson M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 455: 975-8. PMID 18923525 DOI: 10.1038/Nature07397 |
0.329 |
|
2008 |
Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG, Tamayo P, Finn S, Shrestha Y, Boehm JS, ... Meyerson M, et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 455: 547-51. PMID 18794900 DOI: 10.1038/Nature07179 |
0.675 |
|
2008 |
Taylor BS, Barretina J, Socci ND, Decarolis P, Ladanyi M, Meyerson M, Singer S, Sander C. Functional copy-number alterations in cancer. Plos One. 3: e3179. PMID 18784837 DOI: 10.1371/Journal.Pone.0003179 |
0.394 |
|
2008 |
Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, ... ... Meyerson M, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Medicine. 14: 822-7. PMID 18641660 DOI: 10.1038/Nm.1790 |
0.313 |
|
2008 |
Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, Meyerson M, Wong KK, Richards WG, Sugarbaker DJ, Johnson BE, et al. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. British Journal of Cancer. 99: 245-52. PMID 18594528 DOI: 10.1038/Sj.Bjc.6604469 |
0.324 |
|
2008 |
Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, ... ... Meyerson M, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4275-83. PMID 18594010 DOI: 10.1158/1078-0432.Ccr-08-0168 |
0.689 |
|
2008 |
Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 27: 4702-11. PMID 18408761 DOI: 10.1038/Onc.2008.109 |
0.352 |
|
2008 |
Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Research. 68: 664-73. PMID 18245465 DOI: 10.1158/0008-5472.Can-07-2615 |
0.3 |
|
2008 |
Engelsen IB, Stefansson IM, Beroukhim R, Sellers WR, Meyerson M, Akslen LA, Salvesen HB. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. International Journal of Oncology. 32: 307-16. PMID 18202752 DOI: 10.3892/Ijo.32.2.307 |
0.316 |
|
2008 |
Swanson KD, Winter JM, Reis M, Bentires-Alj M, Greulich H, Grewal R, Hruban RH, Yeo CJ, Yassin Y, Iartchouk O, Montgomery K, Whitman SP, Caligiuri MA, Loh ML, Gilliland DG, ... ... Meyerson M, et al. SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. Genes, Chromosomes & Cancer. 47: 253-9. PMID 18064648 DOI: 10.1002/Gcc.20527 |
0.359 |
|
2007 |
Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, ... Meyerson M, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Research. 67: 11924-32. PMID 18089823 DOI: 10.1158/0008-5472.Can-07-1885 |
0.36 |
|
2007 |
Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, ... ... Meyerson M, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America. 104: 20007-12. PMID 18077431 DOI: 10.1073/Pnas.0710052104 |
0.393 |
|
2007 |
Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, ... ... Meyerson M, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 450: 893-8. PMID 17982442 DOI: 10.1038/Nature06358 |
0.419 |
|
2007 |
Getz G, Höfling H, Mesirov JP, Golub TR, Meyerson M, Tibshirani R, Lander ES. Comment on "The consensus coding sequences of human breast and colorectal cancers". Science (New York, N.Y.). 317: 1500. PMID 17872428 DOI: 10.1126/Science.1138764 |
0.321 |
|
2007 |
Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, ... ... Meyerson M, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature. 448: 807-10. PMID 17676035 DOI: 10.1038/Nature06030 |
0.425 |
|
2007 |
Meyerson M. Cancer: Broken genes in solid tumours Nature. 448: 545-546. PMID 17671492 DOI: 10.1038/448545A |
0.458 |
|
2007 |
Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, ... ... Meyerson ML, et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell. 12: 81-93. PMID 17613438 DOI: 10.1016/J.Ccr.2007.06.005 |
0.324 |
|
2007 |
Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, ... ... Meyerson M, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 129: 1065-79. PMID 17574021 DOI: 10.1016/J.Cell.2007.03.052 |
0.38 |
|
2007 |
Yuza Y, Glatt KA, Jiang J, Greulich H, Minami Y, Woo MS, Shimamura T, Shapiro G, Lee JC, Ji H, Feng W, Chen TH, Yanagisawa H, Wong KK, Meyerson M. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biology & Therapy. 6: 661-7. PMID 17495523 DOI: 10.4161/Cbt.6.5.4003 |
0.335 |
|
2007 |
Minami Y, Shimamura T, Shah K, LaFramboise T, Glatt KA, Liniker E, Borgman CL, Haringsma HJ, Feng W, Weir BA, Lowell AM, Lee JC, Wolf J, Shapiro GI, Wong KK, ... Meyerson M, et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene. 26: 5023-7. PMID 17311002 DOI: 10.1038/Sj.Onc.1210292 |
0.405 |
|
2007 |
Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, ... ... Meyerson M, et al. High-throughput oncogene mutation profiling in human cancer. Nature Genetics. 39: 347-51. PMID 17293865 DOI: 10.1038/Ng1975 |
0.363 |
|
2007 |
Thomas RK, Meyerson M. C7-06: Translational lung cancer genomics Journal of Thoracic Oncology. 2: S381-S382. DOI: 10.1097/01.Jto.0000283234.99206.70 |
0.348 |
|
2007 |
Thomas RK, Baker AC, DeBiasi RM, Winckler W, LaFramboise T, Lin WM, Wang M, Feng W, Zander T, MacConnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, ... ... Meyerson M, et al. Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer Nature Genetics. 39: 567-567. DOI: 10.1038/Ng0407-567A |
0.374 |
|
2006 |
Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub T, Meyerson M, Tenen DG, Shapiro GI, Halmos B. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Research. 66: 11389-98. PMID 17145885 DOI: 10.1158/0008-5472.Can-06-2318 |
0.319 |
|
2006 |
Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Research. 66: 8337-41. PMID 16951139 DOI: 10.1158/0008-5472.Can-06-1482 |
0.32 |
|
2006 |
Thomas RK, Weir B, Meyerson M. Genomic approaches to lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4384s-4391s. PMID 16857815 DOI: 10.1158/1078-0432.Ccr-06-0098 |
0.47 |
|
2006 |
Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, et al. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4365s-4371s. PMID 16857812 DOI: 10.1158/1078-0432.Ccr-06-1005 |
0.339 |
|
2006 |
Shimamura T, Ji H, Minami Y, Thomas RK, Lowell AM, Shah K, Greulich H, Glatt KA, Meyerson M, Shapiro GI, Wong KK. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Research. 66: 6487-91. PMID 16818618 DOI: 10.1158/0008-5472.Can-06-0971 |
0.345 |
|
2006 |
Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, ... ... Meyerson M, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nature Medicine. 12: 852-5. PMID 16799556 DOI: 10.1038/Nm1437 |
0.398 |
|
2006 |
Costa DB, Dayaram T, D'Alo F, Wouters BJ, Tenen DG, Meyerson M, Tsao MS, Halmos B. C/EBP alpha mutations in lung cancer. Lung Cancer (Amsterdam, Netherlands). 53: 253-4. PMID 16765476 DOI: 10.1016/J.Lungcan.2006.04.011 |
0.3 |
|
2006 |
Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA, Thomas RK, Sasaki H, Horner JW, Eck M, Mitchell A, ... ... Meyerson M, et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 103: 7817-22. PMID 16672372 DOI: 10.1073/Pnas.0510284103 |
0.337 |
|
2006 |
Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Research. 66: 3162-8. PMID 16540667 DOI: 10.1158/0008-5472.Can-05-3757 |
0.354 |
|
2006 |
Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, ... ... Meyerson M, et al. Erratum: Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing (Nature Medicine (2006) 12 (852-855)) Nature Medicine. 12. DOI: 10.1038/Nm1006-1220A |
0.319 |
|
2005 |
Thomas RK, Greulich H, Yuza Y, Lee JC, Tengs T, Feng W, Chen TH, Nickerson E, Simons J, Egholm M, Rothberg JM, Sellers WR, Meyerson ML. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. Cold Spring Harbor Symposia On Quantitative Biology. 70: 73-81. PMID 16869740 DOI: 10.1101/Sqb.2005.70.056 |
0.394 |
|
2005 |
Garraway LA, Weir BA, Zhao X, Widlund H, Beroukhim R, Berger A, Rimm D, Rubin MA, Fisher DE, Meyerson ML, Sellers WR. "Lineage addiction" in human cancer: lessons from integrated genomics. Cold Spring Harbor Symposia On Quantitative Biology. 70: 25-34. PMID 16869735 DOI: 10.1101/Sqb.2005.70.016 |
0.411 |
|
2005 |
Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor Cancer Research. 65: 7096-7101. PMID 16103058 DOI: 10.1158/0008-5472.Can-05-1346 |
0.302 |
|
2005 |
Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, ... Meyerson ML, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 436: 117-22. PMID 16001072 DOI: 10.1038/Nature03664 |
0.441 |
|
2005 |
Meyerson M, Carbone D. Genomic and proteomic profiling of lung cancers: Lung cancer classification in the age of targeted therapy Journal of Clinical Oncology. 23: 3219-3226. PMID 15886309 DOI: 10.1200/Jco.2005.15.511 |
0.396 |
|
2005 |
Sellers WR, Meyerson M. EGFR gene mutations: a call for global x global views of cancer. Journal of the National Cancer Institute. 97: 326-8. PMID 15741561 DOI: 10.1093/Jnci/Dji079 |
0.411 |
|
2005 |
Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine. 352: 786-92. PMID 15728811 DOI: 10.1056/Nejmoa044238 |
0.369 |
|
2005 |
Cho D, Kocher O, Lee JC, Tenen DG, Meyerson ML, Janne PA, Halmos B. Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 235-7. PMID 15625379 DOI: 10.1200/JCO.2005.07.169 |
0.371 |
|
2004 |
Weir B, Zhao X, Meyerson M. Somatic alterations in the human cancer genome Cancer Cell. 6: 433-438. PMID 15542426 DOI: 10.1016/J.Ccr.2004.11.004 |
0.46 |
|
2004 |
Dubinett SM, Elashoff D, Meyerson M. Assessing prognosis in non-small-cell lung cancer: Avenues to a more complete picture? Journal of Clinical Oncology. 22: 3209-3211. PMID 15249586 DOI: 10.1200/Jco.2004.05.931 |
0.301 |
|
2004 |
Zhao X, Li C, Paez JG, Chin K, Jänne PA, Chen TH, Girard L, Minna J, Christiani D, Leo C, Gray JW, Sellers WR, Meyerson M. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Research. 64: 3060-71. PMID 15126342 DOI: 10.1158/0008-5472.Can-03-3308 |
0.365 |
|
2004 |
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, ... ... Meyerson M, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (New York, N.Y.). 304: 1497-500. PMID 15118125 DOI: 10.1126/Science.1099314 |
0.374 |
|
2004 |
Jänne PA, Li C, Zhao X, Girard L, Chen TH, Minna J, Christiani DC, Johnson BE, Meyerson M. High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene. 23: 2716-26. PMID 15048096 DOI: 10.1038/Sj.Onc.1207329 |
0.375 |
|
2004 |
Meyerson M, Franklin WA, Kelley MJ. Molecular Classification and Molecular Genetics of Human Lung Cancers Seminars in Oncology. 31: 4-19. PMID 14981576 DOI: 10.1053/J.Seminoncol.2003.12.009 |
0.406 |
|
2004 |
Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, Harris L, Ramaswamy S, Tanenbaum DM, Meyerson M, Iglehart JD, Richardson A. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Research. 64: 64-71. PMID 14729609 DOI: 10.1158/0008-5472.Can-03-2570 |
0.339 |
|
2001 |
Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, ... ... Meyerson M, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proceedings of the National Academy of Sciences of the United States of America. 98: 13790-5. PMID 11707567 DOI: 10.1073/Pnas.191502998 |
0.317 |
|
2001 |
Tanenbaum D, Lindblad-Toh K, Lander E, Meyerson M. High-throughput genomic analysis of small-cell lung cancer: allelotyping using Affymetrix HuSNP arrays Nature Genetics. 27: 90-90. DOI: 10.1038/87326 |
0.391 |
|
2000 |
Lindblad-Toh K, Tanenbaum DM, Daly MJ, Winchester E, Lui WO, Villapakkam A, Stanton SE, Larsson C, Hudson TJ, Johnson BE, Lander ES, Meyerson M. Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nature Biotechnology. 18: 1001-5. PMID 10973224 DOI: 10.1038/79269 |
0.317 |
|
2000 |
Meyerson M. Role of telomerase in normal and cancer cells Journal of Clinical Oncology. 18: 2626-2634. PMID 10893296 DOI: 10.1200/Jco.2000.18.13.2626 |
0.38 |
|
Show low-probability matches. |